In this issue:
Apheresis response in relation to histopathologically defined immunopathological patterns of MS
Effect of natalizumab on disease progression in SPMS
Temporal trends in MS prevalence and incidence
Psychiatric comorbidity and disability progression in MS
Sun exposure over the life course and associations with MS
Real-life long-term effectiveness of fingolimod in RRMS patients
No excess of AIDs in MS families from the Netherlands
Identifying neuropathic pain in MS patients
Anti-JCV serology during natalizumab treatment
Treatment response to DMF and lymphocyte subsets
Please login below to download this issue (PDF)